Previous 10 | Next 10 |
Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 first quarter financial results on Tuesday, May 7, 2019, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Fina...
Novartis ( NVS ): The stock has been tumbling after the company announced interim data from the Phase 2 STR1VE trial of Zolgensma/AVXS-101 in spinal muscular atrophy ( SMA ) Type 1. While it's true that prolonged event-free survival and rapid increase in CHOP-INTEND scores were encouragi...
--Eagle’s bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019-- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq:EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has...
Eagle Pharmaceuticals (NASDAQ: EGRX ) has expanded its existing BENDEKA (bendamustine hydrochloride) licensing agreement with Teva Pharmaceuticals (NYSE: TEVA ). More news on: Eagle Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that it has expanded its existing BENDEKA™ (bendamustine hydrochloride) licensing agreement with Teva Pharmaceuticals International GmbH (“Teva”). Under the ...
Eagle Pharmaceuticals Inc. (EGRX) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Scott Tarriff – Founder, Chief Executive Officer and Director David Pernock – President, Chief Commercial Off...
Eagle Pharmaceuticals (NASDAQ: EGRX ): Q4 Non-GAAP EPS of $1.20 beats by $0.04 ; GAAP EPS of $0.86 beats by $0.07 . More news on: Eagle Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Q4 2018 net income was $0.88 per basic and $0.86 per diluted share and adjusted non-GAAP net income was $1.23 per basic and $1.20 per diluted share -- -- FY 2018 net income was $2.16 per basic and $2.09 per diluted share and adjusted non-GAAP net income was $4.01 per basic and $3.87 ...
AAON , ABB , ACIW , AKRX , AMCX , AMRX , BCPC , BID , BMCH , BPMP , BUD , CARS , CM , CMD , CNP , CROX , CWEN , CWT , DAVA , DEA , EGRX , ENDP , EXLS , FOLD , FRO , FSS , GOLF , GTN , GTT , HMHC , HRI , IBP , ICPT , IRDM , JCP , JD , KDP , LAUR , LKQ ,...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...